NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
Clinical Trials
13 trialsNCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04957615 2025-10-30
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05347212 2025-10-10
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05219435 2025-09-24
VEXILLUM
Spanish Oncology Genito-Urinary Group
Phase 2 Active not recruiting
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02832167 2022-05-09
CheckMate 627
Bristol-Myers Squibb
Phase 2 Completed
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT04761744 2021-02-21
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
Phase 2 Unknown
NCT04131621 2020-04-15
CheCUP
University Hospital Heidelberg
Phase 2 Unknown
NCT03864575 2019-07-12
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown